Teruhiko Kozuka
Research Subjects
Research Interests
Teruhiko Kozuka has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Atsuko Ashiba
1 shared publication- Fumihiko Ishimaru
Second Department of Internal Medicine, Okayama University Medical School
1 shared publication Katsuji Shinagawa
1 shared publication- Katsuto Takenaka
Second Department of Internal Medicine, Okayama University Medical School, Japan
1 shared publication - Katsuyuki Kiura
Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
1 shared publication Kazuhiko Yamamoto
1 shared publication
Latest Publications
- 1 January 2001
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 42 (6) , 1297-1303
High-dose Chemotherapy with Hematopoietic Stem Cell Transplantation is Effective for Nasal and Nasal-type CD56 + Natural Killer Cell Lymphomas
CD56+ natural killer (NK) cell lymphomas occur frequently in the nasal and nasopharyngeal regions and carry a poor prognosis. We have studied seven cases with NK-cell lymphomas. These lymphomas showed the following immunophenotype: CD56+, CD2+, sCD3- and Epstein-Barr virus-encoded small RNAs (EBERs)+. Six patients had localized (stage I or II) disease involving the nasopharyngeal region, while one had stage III disease. One patient with stage I disease achieved a complete remission (CR) after treatment with involved-field irradiation, but subsequently relapsed and died. The remaining six patients received combination chemotherapy as primary treatment: five patients with localized stage I or II disease and one patient with advanced stage III disease. Responses to initial chemotherapy were generally poor. These six patients received a variety of salvage chemotherapy regimens, but never achieved a CR. Subsequently, four of six patients showed a highly aggressive clinical course and died of disseminated disease within 1 year from the diagnosis. Three of six patients received high-dose chemotherapy supported by syngeneic, autologous or allogeneic peripheral blood stem cell transplantation. Two of the three transplant patients achieved a CR and are now surviving in continuous CR. Our clinical experience suggests that myeloablative high-dose chemotherapy and bone marrow rescue by hematopoietic stem cell transplantation may be an effective salvage treatment modality for refractory NK-cell lymphomas and could be considered as a part of the initial therapy for these patients.
- 1 January 2001
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 42 (6) , 1297-1303
High-dose Chemotherapy with Hematopoietic Stem Cell Transplantation is Effective for Nasal and Nasal-type CD56 + Natural Killer Cell Lymphomas
CD56+ natural killer (NK) cell lymphomas occur frequently in the nasal and nasopharyngeal regions and carry a poor prognosis. We have studied seven cases with NK-cell lymphomas. These lymphomas showed the following immunophenotype: CD56+, CD2+, sCD3- and Epstein-Barr virus-encoded small RNAs (EBERs)+. Six patients had localized (stage I or II) disease involving the nasopharyngeal region, while one had stage III disease. One patient with stage I disease achieved a complete remission (CR) after treatment with involved-field irradiation, but subsequently relapsed and died. The remaining six patients received combination chemotherapy as primary treatment: five patients with localized stage I or II disease and one patient with advanced stage III disease. Responses to initial chemotherapy were generally poor. These six patients received a variety of salvage chemotherapy regimens, but never achieved a CR. Subsequently, four of six patients showed a highly aggressive clinical course and died of disseminated disease within 1 year from the diagnosis. Three of six patients received high-dose chemotherapy supported by syngeneic, autologous or allogeneic peripheral blood stem cell transplantation. Two of the three transplant patients achieved a CR and are now surviving in continuous CR. Our clinical experience suggests that myeloablative high-dose chemotherapy and bone marrow rescue by hematopoietic stem cell transplantation may be an effective salvage treatment modality for refractory NK-cell lymphomas and could be considered as a part of the initial therapy for these patients.